Figure 1. Significant Improvement in Response Prediction to NAC over SOC using the QPOR™ Platform, N=88
The QPOR™ Platform Predicts Neoadjuvant Chemotherapy Response in Multiple Subgroups of Breast Cancer
- Retrospective analysis of completed Phase II trial with a leading cancer center and national consortium predicting neoadjuvant chemotherapy response in TNBC and HER2-/ER+ breast cancer (N=88)
- The 4D Path QPOR™ indices (signature) used in this study are predictive of neoadjuvant chemotherapy (NAC) response from the images of pre-treatment H&E biopsies across therapies
- Significant improvement in response prediction over current evaluation using standard
clinic-pathological features (Figure 1)
- 40% accuracy using current standard of care method
- >80% using QPOR™ with our default screen and 98% using our customized screen (increase in %Responder >100%)
- Data presented at ASCO 2024
Figure 2. Cohort selection for immunotherapy benefit by QPOR™ Immune Signature Status, N=81
QPOR™ Platform Predicts Response to Immunotherapy in Patients with Metastatic Melanoma
In a retrospective review of 81 metastatic melanoma patients, who were assigned to receive IO therapy based on PDL1, status:
- 36 patients received IO and 45 patients did not
- No statistically meaningful OS was observed (p=0.06).
All patients were stratified using the QPOR™ immune profile, “SVI”, into high and low cohorts,
- In the high cohort, there was a statistically significant difference in outcomes between those who received IO and those who did not (Figure 2)
- Furthermore, using the QPOR™ platform to predict IO therapy response demonstrated >50%
patients received ineffective or inappropriate treatment because current diagnostic tests
are insufficient.
- Significant immunotherapy benefit for 51% (41/81) patients with median 6+ years of improvement in OS
- 28% (23/81) patients would benefit from immunotherapy who would otherwise be missed by current SOC